

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA: Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

One consultee stated that the NHS lung cancer screening pilot has not been rolled out nationally yet. They stated that this may affect how effectively early non-small cell lung cancer patients are diagnosed across the country and that this may lead to equality issues if adjuvant immunotherapy becomes available for patients.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

This is not considered to be an equalities issue as this would not affect people protected by equality legislation any differently than other groups included in the appraisal population.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Not applicable

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes

to the matrix been made?
No additional stakeholders identified.

**Approved by Associate Director (name):** Jasdeep Hayre

**Date:** 18 August 2021